The study evaluates DPP-4 inhibition in obese type 2 diabetes, highlighting potential for therapy.
Spiropyrrolizine 4d emerges as a promising multitarget antidiabetic candidate for OB-T2D management.
No takes yet. Share an insight, caveat, or question.
Abdella et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: